{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061077","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.066816+00:00","generated_at":"2026-06-08T09:06:23.359414+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fate Therapeutics Q3 2023: $350M cash, multiple IND clearances, FT522 enrollment started","bullets":["Cash, cash equivalents & investments $349.7M as of Sept 30, 2023; runway into 2H25.","Revenue $1.9M from ONO collaboration; GAAP operating expenses $53.2M (R&D $34.3M, G&A $18.9M).","FT522 Phase 1 open for enrollment in B-cell lymphoma; 3-dose cohort at 300M cells per dose.","IND cleared for FT825/ONO-8250 CAR T targeting HER2 in solid tumors; Phase 1 start-up ongoing.","IND cleared for FT819 CAR T in systemic lupus erythematosus; Phase 1 design includes single dose with preconditioning."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061077","json":"https://secwatch.observer/filing/0000950170-23-061077.json","markdown":"https://secwatch.observer/filing/0000950170-23-061077.md","text":"https://secwatch.observer/filing/0000950170-23-061077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023061077/0000950170-23-061077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023061077/fate-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:06:23.359414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d7a77b61a44f0c5edcb5975dbc921cb98ef9042","claim":"FATE THERAPEUTICS INC reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 8, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023061077/0000950170-23-061077-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}